US 2017/0283496 A1 · OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION

Abstract

The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.

Claims23

Dependent claims

An antisense oligonucleotide conjugate comprising:

a. an oligonucleotide (Region A) comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity to a PD-L1 target nucleic acid;
and
b. at least one asialoglycoprotein receptor targeting conjugate moiety (Region C) covalently attached to the oligonucleotide in a).

Dependencies are inferred from the claim text.

Facts

Application

15/458,800Filed 14 Mar 2017

Priority

EP 16160149.714 Mar 2016

Published

5 Oct 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification37 codes

C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
A61K 38/1709
From vertebrates: from mammals
A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens

Oligonucleotides for reduction of pd-l1 expression

Life of this patent

Oligonucleotides for reduction of pd-l1 expression

Life of this patent

Abstract

Claims23